Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA

Biomarkers

Volumn 17, Issue 6, 2012, Pages 498-506

  Gorges, Tobias M ^a   Schiller, Johanna ^a   Schmitz, Arndt ^a   Schuetzmann, Daniel ^a   Schatz, Christoph ^a   Zollner, Thomas M ^a   Krahn, Thomas ^a   Von Ahsen, Oliver ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

AluJ; BAY 869766; Biomarker; CtDNA; Xenograft

Indexed keywords

BAY 869766; CIRCULATING TUMOR DNA; DNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATIENT MONITORING; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; SENSITIVITY ANALYSIS; SINGLE CELL ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIPHENYLAMINE; DNA; FEMALE; HUMANS; KINETICS; MALE; MICE; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; SULFONAMIDES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865803081     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.689133     Document Type: Article

References (34)

1. Bennett EA, Keller H, Mills RE, Schmidt S, Moran JV, Weichenrieder O, Devine SE. (2008). Active Alu retrotransposons in the human genome. Genome Res 18:1875-1883.
2. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, Medeiros R. (2008). Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 27:415-421.
3. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, Barriuso J, Moreno Garcia V, Larrauri J, Lopez R, Casado E, Gonzalez-Baron M, Feliu J. (2009). KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis. PLoS ONE 4:e8199.
4. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM. (2002). Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 94:1697-1703.
5. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr. (2008). Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990.
6. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M. (2005). Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65:1141-1145.
7. Garcia-Olmo DC, Gutierrez-Gonzalez L, Samos J, Picazo MG, Atienzar M, Garcia-Olmo D. (2006). Surgery and hematogenous dissemination: Comparison between the detection of circulating tumor cells and of tumor DNA in plasma before and after tumor resection in rats. Ann Surg Oncol 13:1136-1144.
8. Garcia-Olmo DC, Samos J, Picazo MG, Asensio AI, Toboso I, Garcia- Olmo D. (2008). Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett 272:133-140.
9. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. (2004). Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22:4157-4164.
10. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, Hamatake R, Miner JN, Quart B. (2009). RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 69:6839-6847.
11. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. (2001). DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-1665.
12. Jung K, Fleischhacker M, Rabien A. (2010). Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411:1611-1624.
13. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, Simpson JL, Sood AK. (2006). Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 5:1369-1374.
14. Koffler D, Agnello V, Winchester R, Kunkel HG. (1973). The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52:198-204.
15. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650.
16. Leon SA, Ehrlich GE, Shapiro B, Labbate VA. (1977). Free DNA in the serum of rheumatoid arthritis patients. J Rheumatol 4:139-143.
17. Li CN, Hsu HL, Wu TL, Tsao KC, Sun CF, Wu JT. (2003). Cell-free DNA is released from tumor cells upon cell death: A study of tissue cultures of tumor cell lines. J Clin Lab Anal 17:103-107.
18. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. (1999). Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218-224. 506 T. M. Gorges et al. Biomarkers Mendel P, Metais P. (1948). Les acides nucleiques du plasma sanguin chez l'homme. C R Acad Sci Paris 142:241-243.
19. Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR. (2011). High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE 6:e23418.
20. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, Samuels Y, Velculescu VE, Vogelstein B, Kinzler KW, Diaz LA Jr. (2007). Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 67:9364-9370.
21. Samos J, Garcia-Olmo DC, Picazo MG, Rubio-Vitaller A, Garcia- Olmo D. (2006). Circulating nucleic acids in plasma/serum and tumor progression: Are apoptotic bodies involved? An experimental study in a rat cancer model. Ann N Y Acad Sci 1075:165-173.
22. Schmidt B, Weickmann S, Witt C, Fleischhacker M. (2008). Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci 1137:207-213.
23. Schneider T, Osl F, Friess T, Stockinger H, Scheuer WV. (2002). Quantification of human Alu sequences by real-time PCR-an improved method to measure therapeutic efficacy of antimetastatic drugs in human xenotransplants. Clin Exp Metastasis 19:571-582.
24. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. (2008). Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci 1137:190-196.
25. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. (1983). Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116-2120.
26. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P. (2000). The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906:161-168.
27. Su YH, Wang M, Brenner DE, Norton PA, Block TM. (2008). Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci 1137:197-206.
28. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. (2008). Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci 1137:171-174.
29. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F. (2010). Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38:6159-6175.
30. van der Vaart M, Pretorius PJ. (2008). Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137:18-26.
31. van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, van der Stappen JW, Dekhuijzen PN, van der Heijden HF, Thunnissen FB. (2010). Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68:283-287.
32. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577.
33. Ziegler A, Zangemeister-Wittke U, Stahel RA. (2002). Circulating DNA: A new diagnostic gold mine? Cancer Treat Rev 28:255-271.
34. Zitt M, Muller HM, Rochel M, Schwendinger V, Zitt M, Goebel G, Devries A, Margreiter R, Oberwalder M, Zeillinger R, Ofner D. (2008). Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: A potential diagnostic tool for therapy monitoring. Dis Markers 25:159-165.